Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 4, 2010, Pages 396-399

  Ponsen, Mirthe M ^a   Stoffers, Diederick ^a   Wolters, Erik Ch ^a   Booij, Jan ^b   Berendse, Henk W ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER I 123; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; LEVODOPA; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; FOLLOW UP; HUMAN; HYPOSMIA; MAJOR CLINICAL STUDY; NIGRONEOSTRIATAL SYSTEM; OLFACTORY DISCRIMINATION; PARKINSON DISEASE; PARKINSONISM; PREDICTION; PRIORITY JOURNAL; PUTAMEN; QUESTIONNAIRE; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMELLING; TASK PERFORMANCE;

AGED; BRAIN; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MALE; MIDDLE AGED; OLFACTION DISORDERS; PARKINSON DISEASE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77950601138     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.183715     Document Type: Article

References (20)

1. Marek K, Innis R, van Dyck C, et al. [(123) I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001; 57:2089-94.
2. Morrish PK, Rakshi JS, Bailey DL, et al. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatr 1998;64:314-9.
3. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-301.
4. Hirsch EC. How to improve neuroprotection in Parkinson's disease? Parkinsonism Relat Disord 2007;13(Suppl 3):S332-5.
5. Hart RG, Pearce LA, Ravina BM, et al. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord 2009;24:647-54.
6. Berendse HW, Booij J, Francot CM, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 2001;50:34-41.
7. Piccini P, Burn DJ, Ceravolo R, et al. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999;45:577-82.
8. Ponsen MM, Stoffers D, Booij J, et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004;56:173-81.
9. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008;63:167-73.
10. Haehner A, Hummel T, Hummel C, et al. Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord 2007;22:839-42.
11. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatr 1988;51:745-52.
12. Duarte J, Claveria LE, Pedro-Cuesta J, et al. Screening Parkinson's disease: a validated questionnaire of high specificity and sensitivity. Mov Disord 1995;10:643-49.
13. Booij J, Tissingh G, Winogrodzka A, et al. Practical benefit of [123I]FP-CIT SPECT in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997;24:68-71.
14. de Win MM, Habraken JB, Reneman L, et al. Validation of [(123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology 2005;30:996-1005.
15. Postuma RB, Gagnon JF, Vendette M, et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009;14:1296-300.
16. Khan NL, Valente EM, Bentivoglio AR, et al. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol 2002;52:849-53.
17. Adams JR, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005;128:2777-85.
18. Praschak-Rieder N, Willeit M, Wilson AA, et al. Seasonal variation in human brain serotonin transporter binding. Arch Gen Psychiatry 2008;65:1072-78.
19. Buchert R, Schulze O, Wilke F, et al. Is correction for age necessary in SPECT or PET of the central serotonin transporter in young, healthy adults? J Nucl Med 2006;47:38-42.
20. Ruhe HG, Booij J, Reitsma JB, et al. Serotonin transporter binding with [(123)I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender. Eur J Nucl Med Mol Imaging 2009;36:841-49.